Dyslipidemia and cardiovascular risk among hypertensive patients at primary healthcare facilities
Main Article Content
Abstract
Dyslipidemia is common among hypertensive patients and increases cardiovascular risk. This cross-sectional study was conducted from June 2022 to September 2023 in four communes/townships of Lam Thao district, Phu Tho province. 962 hypertensive patients aged 40 years or older managed at commune health stations for at least three months were enrolled. The study aimed to determine the prevalence of dyslipidemia and assess total cardiovascular risk using SCORE2/SCORE2-OP/SCORE2-Diabetes, and evaluate the attainment of risk-stratified LDL-C targets. The prevalence of dyslipidemia was 86.1%, with 63.7% having abnormalities in at least two lipid components. The proportion with LDL-C ≥ 2.6 mmol/L was 74.7%. The mean absolute cardiovascular risk score was high in both men and women (22.3 ± 12.0 and 25.6 ± 15.8, respectively). Most patients were classified as very high risk (51.2%) or high risk (30.7%). Only 8.9% achieved risk-stratified LDL-C targets, and 6.2% achieved both LDL-C and blood pressure targets. Integrated lipid and blood pressure management should be strengthened at the primary healthcare level.
Article Details
Keywords
Dyslipidemia, hypertension, cardiovascular risk, SCORE2, primary healthcare
References
2. Gorder D, Dolecek T, Coleman G, Tillotson J, Brown H, Lenz-Litzow K. Dietary intake in the Multiple Risk Factor Intervention Trial (MRFIT): nutrient and food group changes over 6 years. J Am Diet Assoc. 1986; 86(6): 744-751.
3. Han B, Sutin D, Williamson J, Davis B, Piller L, Pervin H. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: the ALLHAT-LLT randomized clinical trial. JAMA Intern Med. 2017; 177(7): 955-965. doi:10.1001/jamainternmed.2017.1442.
4. Sever P, Dahlöf B, Poulter N, Wedel H, Beevers G, Caulfield M. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361(9364): 1149-1158. doi:10.1016/S0140-6736(03)12948-0.
5. Baigent C, Blackwell L, Emberson J, Holland L, Reith C, Bhala N. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753): 1670-1681. doi:10.1016/S0140-6736(10)61350-5.
6. Jones D, Ferdinand K, Taler S, Johnson H, Shimbo D. 2025 AHA/ACC guideline for the prevention, detection, evaluation and management of high blood pressure in adults. Circulation. 2025; 152(11): e114-e218. doi:10.1161/CIR.0000000000001356.
7. Mach F, Baigent C, Catapano A, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020; 41(1): 111-188.
8. Visseren F, Mach F, Smulders Y, Carballo D, Koskinas K, Bäck M. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227-3337. doi:10.1093/eurheartj/ehab484.
9. Trần Tất Thắng, Hoàng Thị Tâm. Đặc điểm rối loạn lipid máu ở 2 nhóm bệnh nhân tăng huyết áp và không tăng huyết áp điều trị ngoại trú tại Bệnh viện Đa khoa thành phố Vinh (2022). Tạp chí Y học Việt Nam. 2022; 520(1A): 322-325. doi:10.51298/vmj.v520i1A.3799.
10. World Health Organization Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363(9403): 157-163. doi:10.1016/S0140-6736(03)15268-3.
11. American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: Standards of Care in Diabetes--2024. Diabetes Care. 2024; 47(Suppl 1): S20-S42. doi:10.2337/dc24-S002
12. World Health Organization. WHO STEPS Surveillance Manual: The WHO STEPwise Approach to Noncommunicable Disease Risk Factor Surveillance. World Health Organization; 2017.
13. Nguyễn Thị Hồng Thủy. Nghiên cứu rối loạn lipid máu ở người cao tuổi có tăng huyết áp tại Bệnh viện Đa khoa tỉnh Phú Yên. Tạp chí Y học Việt Nam. 2013; 2(12): 217-226.